This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Vision-Sciences Selected As Preferred Vendor For Endoscopy Equipment By 21st Century Oncology

Stocks in this article: VSCI

Orangeburg, NY, Dec. 19, 2013 (GLOBE NEWSWIRE) -- Orangeburg, NY - December 19, 2013- Vision-Sciences, Inc. (NASDAQ: VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath® technology, has entered into an agreement with 21 st Century Oncology, Inc., under which Vision-Sciences is 21 st Century's Preferred Vendor of Choice for endoscopy equipment used for evaluation and treatment procedures in multiple therapeutic and cancer care areas.  The equipment agreement includes several of the company's advanced fiberoptic and video based endoscopic imaging products, including flexible laryngoscopes, transnasal esophagoscopes, bronchoscopes, and cystoscopes, all of which are utilized in the diagnosing, treatment, and management of head and neck, esophageal, lung, and bladder cancers.

"We are pleased to have forged this multi-disciplinary agreement with 21 st Century Oncology, Inc.  This is another important validation of our 'always ready, always sterile' EndoSheath technology platform, which provides high-quality endoscopy while protecting patients against the hazards of inadequate endoscopic reprocessing," said Howard Zauberman, President and Chief Executive Officer of Vision-Sciences.  "We look forward to the continued growth of our franchise enabled by this agreement, which affords us the opportunity to outfit each of 21 st Century's 166 treatment centers in the U.S. and Latin America with state of the art imaging technology and the only sterile endoscopic solution in the market.

"In keeping with our commitment to delivering high quality care for patients, we have selected Vision-Sciences as our Preferred Vendor of Choice for endoscopy equipment," said Kathy Tolentino, Director Purchasing, 21st Century Oncology, Inc.  "Vision-Sciences' EndoSheath technology offers the only sterile, disposable option in flexible endoscopic treatment for the enhanced safety of patients.  This agreement provides us the most efficient and cost-effective manner to perform safe, efficacious endoscopic management."

About Vision-Sciences, Inc.

Vision-Sciences, Inc. designs, develops, manufactures and markets products for flexible endoscopy. The Company's unique product lines feature a streamlined visualization system and proprietary sterile disposable microbial barrier, known as EndoSheath ® technology, providing users with efficient and cost effective endoscope turnover while enhancing patient safety.  Information about Vision-Sciences' products is available at .

Vision-Sciences owns the trademarks Vision Sciences™ and Slide-On™ and the registered trademarks EndoSheath ®, EndoWipe ® and The Vision System ®.

About 21 st Century

21 st Century Oncology, Inc., which operates and manages radiation treatment centers primarily under the name 21st Century Oncology, offers a comprehensive range of radiation treatment alternatives and focuses on delivering academic-quality, cost-effective patient care in a personal and convenient setting.  The Company operates 166 treatment centers, including 133 centers located in 16 U.S. states and 33 centers in six Latin American countries. The Company holds market-leading positions in most of its domestic local markets and abroad.  21 st Century Oncology is headquartered in Fort Myers, Florida.


Keith Darragh                                                                                                                       Lisa Wilson

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs